BRIEF published on 06/13/2024 at 09:41, 2 years 5 months ago Crossject : Information sur le nombre de droits de vote et d'actions Droits De Vote Capital Social Actions 2024 Crossject
BRIEF published on 06/13/2024 at 09:41, 2 years 5 months ago Crossject: Information on the number of voting rights and shares Share Capital Voting Rights Actions 2024 Crossject
PRESS RELEASE published on 06/13/2024 at 09:36, 2 years 5 months ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Crossject publie le nombre total de droits de vote et d'actions au 31 mai 2024 conformément aux normes réglementaires Droits De Vote Capital Social Actions Crossject Pharma
BRIEF published on 06/12/2024 at 07:35, 2 years 5 months ago Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord Crossject ZEPIZURE® Dan Chiche Directeur Médical
BRIEF published on 06/12/2024 at 07:35, 2 years 5 months ago Crossject Appoints Dan Chiche, MD as North America Chief Medical Officer Crossject ZEPIZURE® Dan Chiche Medical Director
PRESS RELEASE published on 06/12/2024 at 07:30, 2 years 5 months ago Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord Nomination de Dan Chiche, MD en tant que Directeur Médical Amérique du Nord chez Crossject, renforçant l'équipe dirigeante et la présence aux États-Unis pour lancer ZEPIZURE en 2025 Amérique Du Nord Crossject ZEPIZURE Dan Chiche Directeur Médical
PRESS RELEASE published on 06/12/2024 at 07:30, 2 years 5 months ago Crossject appoints Dan Chiche, MD as Chief Medical Officer North America Crossject appoints Dan Chiche, MD as Chief Medical Officer North America, strengthening leadership team and expanding presence in U.S. Supports ZEPIZURE® regulatory milestones targeting in 2025 North America Chief Medical Officer Crossject ZEPIZURE Dan Chiche
BRIEF published on 06/04/2024 at 19:35, 2 years 5 months ago Crossject Announces Successful Closing of €8 Million Rights Offering FDA Approval Rights Offering Crossject ZEPIZURE® Epilepsy Treatment
BRIEF published on 06/04/2024 at 19:35, 2 years 5 months ago Crossject annonce la clôture réussie d'une offre de droits de 8 millions d'euros Approbation De La FDA Offre De Droits ZEPIZURE® Projet Croisé Traitement De L'épilepsie
PRESS RELEASE published on 06/04/2024 at 19:30, 2 years 5 months ago Crossject announces highly successful closing of its €8 million rights offering Crossject successfully closes €8 million rights offering, securing funding for ZEPIZURE® development and FDA approval. Gemmes Venture remains a key supporter FDA Approval Rights Offering Crossject ZEPIZURE® Gemmes Venture
Published on 11/20/2026 at 15:00, 1 day 9 hours ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 1 day 9 hours ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 1 day 10 hours ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 1 day 10 hours ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 1 day 10 hours ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 22:39, 1 day 1 hour ago ABIVAX: Abivax publie une déclaration concernant le rapport d'un vendeur à découvert
Published on 11/20/2026 at 21:36, 1 day 2 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 20:49, 1 day 3 hours ago E-PANGO: Jugement du Tribunal Judiciaire de Paris relatif au contentieux avec le groupement RIVP-HENEO-HSF
Published on 11/20/2026 at 18:34, 1 day 5 hours ago Déclaration hebdomadaire d'opérations effectuées du 16 au 20 novembre 2026
Published on 11/20/2026 at 18:34, 1 day 5 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 6 hours ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 16 au 20 novembre 2026
Published on 11/20/2026 at 17:35, 1 day 6 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 5 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR